YORK, Sept. 16, 2022 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action lawsuit has
commenced on behalf of shareholders of Ampio Pharmaceuticals, Inc.
To receive updates on the lawsuit, fill out the
This lawsuit is on behalf of all persons or entities that
purchased or otherwise acquired Ampio common stock between
December 29, 2020 and August 3, 2022, inclusive.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
October 17, 2022 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
According to a filed complaint, Ampio Pharmaceuticals, Inc.
issued materially false and/or misleading statements and/or failed
to disclose that: (i) defendants had inflated the Company's true
ability to successfully file a Biologics License Application
("BLA") for Ampion; (ii) defendants had inflated the results of the
AP-013 study and the timing of unblinding the data from the AP-013
study; and (iii) as a result of the foregoing, defendants'
statements about the Company's business, operations, and prospects
were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities fraud. Attorney
advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE Jakubowitz Law